Individual Patient Expanded Access IND of Autologous HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE)
- Conditions
- System; Lupus Erythematosus
- Registration Number
- NCT04907175
- Lead Sponsor
- Hope Biosciences Stem Cell Research Foundation
- Brief Summary
This protocol is part of an FDA Individual Patient Expanded Access IND. This study is to be conducted according to US and International Standards of Good Clinical Practice (FDA Title 21 part 312 and International Conference on Harmonization guidelines), applicable government regulations and Hope Biosciences Stem Cell Research Foundation policies and procedures.
- Detailed Description
This Individual Patient Expanded Access IND has been created per the request of a 65-year-old woman diagnosed with Systemic Lupus Erythematosus (SLE).
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
- Adult individual 18 years of age or older.
- Cognitively intact and capable of giving informed consent.
- Clinical diagnosis of Systemic Lupus Erythematosus.
- Subject has mesenchymal stem cells banked at Hope Biosciences.
- The patient accepts to receive treatment and to comply with follow-up visits.
Read More
Exclusion Criteria
- Clinically significant, uncontrolled cardiovascular, lung, renal, hepatic, or endocrine diseases that in the opinion of the investigator may increase the risks associated with study participation.
- Active Alcohol or Drug addiction.
- Participation in concurrent interventional research studies during this study.
- Severe organ failure (heart, kidney or liver) confirmed by additional tests or medical history.
- Unwillingness to return for follow-up visits.
Read More
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Hope Biosciences Stem Cell Research Foundation
🇺🇸Sugar Land, Texas, United States